BioCryst Pharmaceuticals Inc (BCRX)
6.20
+0.09
(+1.47%)
USD |
NASDAQ |
Jun 28, 16:00
6.21
+0.01
(+0.16%)
After-Hours: 20:00
BioCryst Pharmaceuticals Research and Development Expense (TTM): 214.67M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 214.67M |
| December 31, 2023 | 216.57M |
| September 30, 2023 | 219.72M |
| June 30, 2023 | 225.58M |
| March 31, 2023 | 236.32M |
| December 31, 2022 | 253.30M |
| September 30, 2022 | 243.62M |
| June 30, 2022 | 240.85M |
| March 31, 2022 | 231.73M |
| December 31, 2021 | 208.81M |
| September 30, 2021 | 180.63M |
| June 30, 2021 | 160.91M |
| March 31, 2021 | 135.53M |
| December 31, 2020 | 122.96M |
| September 30, 2020 | 114.38M |
| June 30, 2020 | 109.26M |
| March 31, 2020 | 109.44M |
| December 31, 2019 | 107.07M |
| September 30, 2019 | 103.72M |
| June 30, 2019 | 100.61M |
| March 31, 2019 | 93.94M |
| December 31, 2018 | 84.89M |
| September 30, 2018 | 78.38M |
| June 30, 2018 | 73.88M |
| March 31, 2018 | 68.63M |
| Date | Value |
|---|---|
| December 31, 2017 | 66.96M |
| September 30, 2017 | 62.20M |
| June 30, 2017 | 58.79M |
| March 31, 2017 | 57.20M |
| December 31, 2016 | 61.01M |
| September 30, 2016 | 67.90M |
| June 30, 2016 | 73.86M |
| March 31, 2016 | 76.22M |
| December 31, 2015 | 72.76M |
| September 30, 2015 | 72.22M |
| June 30, 2015 | 65.19M |
| March 31, 2015 | 59.73M |
| December 31, 2014 | 51.80M |
| September 30, 2014 | 48.75M |
| June 30, 2014 | 43.45M |
| March 31, 2014 | 43.91M |
| December 31, 2013 | 41.94M |
| September 30, 2013 | 35.26M |
| June 30, 2013 | 39.60M |
| March 31, 2013 | 40.85M |
| December 31, 2012 | 49.16M |
| September 30, 2012 | 54.58M |
| June 30, 2012 | 57.61M |
| March 31, 2012 | 59.28M |
| December 31, 2011 | 57.15M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
100.61M
Minimum
Jun 2019
253.30M
Maximum
Dec 2022
176.78M
Average
194.72M
Median
Research and Development Expense (TTM) Benchmarks
| Integra Lifesciences Holdings Corp | 104.43M |
| Nortech Systems Inc | 1.241M |
| Novavax Inc | 583.08M |
| SINTX Technologies Inc | 8.516M |
| Allogene Therapeutics Inc | 214.94M |